Get the Stockscreener App
21.18
7.91%
-1.82
After Hours:
21.14
-0.04
-0.19%
Lenz Therapeutics Inc stock is traded at $21.18, with a volume of 533.82K.
It is down -7.91% in the last 24 hours and down -1.53% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$23.00
Open:
$21.75
24h Volume:
533.82K
Relative Volume:
3.00
Market Cap:
$583.36M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-3.784
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-17.39%
1M Performance:
-1.53%
6M Performance:
-17.84%
1Y Performance:
+0.00%
1-Day Range:
$20.08
$22.02
1-Week Range:
$20.08
$27.30
52-Week Range:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
21.18 | 583.36M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Presbyopia Treatment Market Size in 7MM is expected to grow at - openPR.com
18,900 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Swiss National Bank - Defense World
Swiss National Bank Takes $546,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Brokers Issue Forecasts for LENZ Q2 Earnings - Defense World
What is Leerink Partnrs’ Forecast for LENZ Q1 Earnings? - Defense World
Citigroup Increases LENZ Therapeutics (NASDAQ:LENZ) Price Target to $47.00 - MarketBeat
William Blair Issues Negative Outlook for LENZ Earnings - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00 - Defense World
Equities Analysts Offer Predictions for LENZ FY2026 Earnings - Defense World
What is HC Wainwright’s Estimate for LENZ Q1 Earnings? - Defense World
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook - TipRanks
Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Strong Market Position and Upcoming Product Launch - TipRanks
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Citi raises LENZ Therapeutics price target to $47, keeps Buy rating - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism By Investing.com - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism - Investing.com
Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView
Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress - MSN
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive - Investing.com India
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive By Investing.com - Investing.com UK
LENZ Therapeutics, Inc. SEC 10-K Report - TradingView
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
LENZ Therapeutics Secures FDA Decision Date with $209M War Chest for Presbyopia Drug Launch - StockTitan
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by TD Cowen - Defense World
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target - Investing.com Canada
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target By Investing.com - Investing.com South Africa
TD Cowen Initiates LENZ Therapeutics at Buy With $60 Price Target -March 18, 2025 at 07:09 am EDT - Marketscreener.com
American Electric Power, Block and Lenz Therapeutics - TradingView
LENZ THERAPEUTICS Earnings Preview: Recent $LENZ Insider Trading, Hedge Fund Activity, and More - Nasdaq
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 - The Manila Times
LENZ Therapeutics Q4 Earnings: Key Updates Coming on Presbyopia Eye Drops - StockTitan
Rhumbline Advisers Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Host Commercial Day on April 15, 2025 - The Manila Times
Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - StockTitan
Insiders Enjoy US$227k Return After Buying LENZ Therapeutics Stock - Simply Wall St
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at Upcoming Investor Conferences in March 2025 - Nasdaq
Can LENZ's Novel Presbyopia Treatment Disrupt the $8B Eye Care Market? Key Investor Presentations Coming - StockTitan
Myopia And Presbyopia Eye Drops Market Future Business - openPR
LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday - Defense World
LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k - Yahoo Finance UK
Citi maintains Buy on LENZ Therapeutics, target at $44 By Investing.com - Investing.com Canada
Citi maintains Buy on LENZ Therapeutics, target at $44 - Investing.com
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):